Source:http://linkedlifedata.com/resource/pubmed/id/10880016
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2000-10-18
|
| pubmed:abstractText |
BLK mouse fibroblasts (H-2b) were genetically engineered to express costimulatory B7.1 and interleukin-2 (BLK/IL2/B7.1). The BLK/IL2/B7.1 cells were then pulsed with an ovalbumin (OVA) epitope as a model antigen (Ag) (BLK/IL2/B7.1/OVA), and tested for the induction of OVA-specific cytotoxic T lymphocytes (CTLs) in C57BL/6 mice (H-2b). The genetically engineered fibroblasts lacking one or two of three factors (interleukin-2, B7.1, and OVA) were constructed and used as controls. Immunization with the BLK/IL2/B7.1/OVA cells induced strong cytotoxic activities against OVA-expressing EL4 (EG7) tumor cells, but not against other H-2b tumor cells, such as EL4, C1498 and B16F1 cells. The magnitude of the cytotoxic response in mice with the BLK/IL2/B7.1/OVA cells was significantly higher than the response in mice immunized with any other cell constructs. CD8+ T cells with OVA-specific cytotoxic activities were predominant in mice immunized with the BLK/IL2/B7.1/OVA cells. Furthermore, immunization with the BLK/IL2/B7.1/OVA cells significantly prolonged the survival of mice, compared with any other cell constructs, when the mice were challenged with EG7 tumor cells at 2 weeks postimmunization. Induction of antitumoral CTL immunity by the BLK/IL2/B7.1/OVA cells was independent of host Ag-presenting cells and of CD4+ T-cell and natural killer 1.1+ cell help. These results suggest that fibroblasts can be genetically modified to efficient Ag-presenting cells for the induction of an Ag-specific CTL response.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0929-1903
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
7
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
861-9
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:10880016-Animals,
pubmed-meshheading:10880016-Antigen Presentation,
pubmed-meshheading:10880016-Antigen-Presenting Cells,
pubmed-meshheading:10880016-Antigens, CD80,
pubmed-meshheading:10880016-CD4-Positive T-Lymphocytes,
pubmed-meshheading:10880016-CD8-Positive T-Lymphocytes,
pubmed-meshheading:10880016-Epitopes,
pubmed-meshheading:10880016-Female,
pubmed-meshheading:10880016-Fibroblasts,
pubmed-meshheading:10880016-Flow Cytometry,
pubmed-meshheading:10880016-Fluorescent Antibody Technique,
pubmed-meshheading:10880016-Gene Therapy,
pubmed-meshheading:10880016-Genetic Engineering,
pubmed-meshheading:10880016-Immunization,
pubmed-meshheading:10880016-Immunotherapy,
pubmed-meshheading:10880016-Interleukin-2,
pubmed-meshheading:10880016-Killer Cells, Natural,
pubmed-meshheading:10880016-Mice,
pubmed-meshheading:10880016-Mice, Inbred BALB C,
pubmed-meshheading:10880016-Mice, Inbred C57BL,
pubmed-meshheading:10880016-Neoplasms,
pubmed-meshheading:10880016-Ovalbumin,
pubmed-meshheading:10880016-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:10880016-Transfection,
pubmed-meshheading:10880016-Tumor Cells, Cultured
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
|
| pubmed:affiliation |
College of Pharmacy, Chonnam National University, Kwangju, Republic of Korea. taekim@chonnam.chonnam.ac.kr
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|